BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.730
+0.250 (16.89%)
At close: Mar 9, 2026, 4:00 PM EDT
1.730
0.00 (0.00%)
Pre-market: Mar 10, 2026, 5:02 AM EDT

BioXcel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2016
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2016
Market Capitalization
3819866025691,126
Upgrade
Market Cap Growth
563.76%-78.51%-85.65%5.82%-49.47%327.27%
Upgrade
Enterprise Value
1118396462317895
Upgrade
Last Close Price
1.735.9847.20343.68325.28739.20
Upgrade
PS Ratio
50.318.1962.581605.17--
Upgrade
PB Ratio
--0.20-1.537.842.575.45
Upgrade
P/TBV Ratio
---7.842.575.45
Upgrade
EV/Sales Ratio
147.5336.6969.821233.33--
Upgrade
Debt / Equity Ratio
-1.23-1.11-1.791.220.010.01
Upgrade
Net Debt / Equity Ratio
-0.82-0.78-0.63-1.30-1.05-1.02
Upgrade
Net Debt / EBITDA Ratio
-1.46-1.13-0.210.632.172.58
Upgrade
Net Debt / FCF Ratio
-1.26-1.01-0.230.742.813.18
Upgrade
Asset Turnover
0.020.040.010.00--
Upgrade
Inventory Turnover
0.971.610.63---
Upgrade
Quick Ratio
0.961.352.405.9013.9818.00
Upgrade
Current Ratio
1.181.682.656.1714.2118.33
Upgrade
Return on Equity (ROE)
---1766.94%-111.08%-49.93%-70.35%
Upgrade
Return on Assets (ROA)
-67.31%-72.30%-74.95%-44.81%-29.10%-40.13%
Upgrade
Return on Capital Employed (ROCE)
-721.90%-402.40%-361.00%-92.30%-48.00%-39.50%
Upgrade
Earnings Yield
-180.29%-321.18%-207.35%-27.54%-18.80%-7.30%
Upgrade
FCF Yield
-153.87%-388.15%-179.52%-22.51%-14.52%-5.92%
Upgrade
Buyback Yield / Dilution
-235.79%-39.21%-4.00%-6.23%-21.63%-33.11%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.